SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will host a science briefing on Tuesday, September 16, 2008 at 12:00pm Eastern Time in New York City. Keynote speaker Dr. Peter Libby, Chief of Cardiovascular Medicine at the Brigham and Women's Hospital and Mallinckrodt Professor of Medicine at Harvard Medical School, will present "Inflammation in Atherosclerosis: Theory and Practice." Following Dr. Libby's presentation, Dr. Lawrence K. Cohen, chief executive officer of VIA Pharmaceuticals, will moderate an expert panel.
"We are pleased to have Dr. Libby speak about the importance of inflammation in atherosclerosis," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "While there are a number of currently available therapies that help reduce risk factors of heart disease, they do not address inflammation, an underlying cause of atherosclerosis and complications such as heart attack and stroke."
Dr. Libby is the Chief of Cardiovascular Medicine at the Brigham and
Women's Hospital in Boston, Massachusetts and serves as the Mallinckrodt
Professor of Medicine at Harvard Medical School. He also directs the D.W.
Reynolds Cardiovascular Clinical Research Center at Harvard. His current
major research focus is the role of inflammation in vascular diseases such
as atherosclerosis. Dr. Libby has received numerous awards and recognitions
for his research accomplishments. His areas of clinical expertise include
general and preventive cardiology. Dr. Libby writes a cardiovascular blog,
"Consults-Experts on the Front Lines of Medicine", for
|SOURCE VIA Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved